Navigation Links
Baron and Budd GranuFlo Lawsuit Lawyers Reviewing Claims Made By Dialysis Patients Allegedly Injured by GranuFlo
Date:10/19/2013

ST. LOUIS (PRWEB) October 19, 2013

The GranuFlo recall lawyers at Baron and Budd are reviewing GranuFlo claims relating to the March 2012 GranuFlo and NaturaLyte recall. Dialysis concentrates used during dialysis treatments to help clean the blood, both GranuFlo and NaturaLyte are manufactured and marketed by Fresenius Medical Care, the world's largest provider of dialysis products. Both dialysis concentrates were recalled by the Food and Drug Administration (FDA) as a Class I recall, the highest form of drug recall in the United States used only when a medical product can cause serious health conditions or even death. (http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm309990.htm)

Dialysis patients or their loved ones may be eligible to file a GranuFlo lawsuit with Baron and Budd's GranuFlo recall lawyers if they suffered from a heart attack during or following a dialysis treatment. This dialysis treatment may have involved the use of GranuFlo or NaturaLyte and therefore could be the cause of the patient's injury.

At this time, Baron and Budd is continuing to review GranuFlo lawsuit claims, providing individuals who may be eligible to file a GranuFlo lawsuit claim with a free legal consultation. All consultations are confidential.

The risk of heart attack associated with the use of GranuFlo and NaturaLyte involves the increased bicarbonate associated with these particular dialysis concentrates. Both GranuFlo and NaturaLyte are more likely to cause a higher level of bicarbonate in the blood compared to other dialysis concentrates in their class. As doctors were uninformed of the increased bicarbonate associated with GranuFlo and NaturaLyte, patients were in turn put at risk for heart attacks allegedly caused by an overdose of bicarbonate. (http://www.prweb.com/releases/2013/5/prweb10700127.htm)

"The FDA does not take Class I recalls lightly. These recalls occur only when there is a reasonable probability that the product could cause serious health condition or even death," says Russell Budd of Baron and Budd. “While the Class I recall is an important step in ensuring dialysis patient safety, work needs to be done to help patients who have already been injured. Our GranuFlo lawyers are taking the necessary steps to help these injured patients by providing confidential and free consultations to patients who have suffered heart attacks following dialysis treatment."

To learn more about Baron and Budd's work on the GranuFlo lawsuit please visit the firm's website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/

To speak with a GranuFlo lawyer as part of Baron and Budd's free and confidential GranuFlo recall consultations, please call 1.866.472.9108.

About Baron & Budd, P.C.

With a history of over 35 years “Protecting What’s Right” for individuals, communities, and governmental entities, Baron and Budd is a well-established law firm devoted to making a positive difference. With offices in Dallas, Austin, Los Angeles and Baton Rouge, Baron and Budd is able to take on complicated and expensive cases within the realms of dangerous drugs and medical devices, asbestos-related illnesses, consumer fraud, water contamination, the Gulf oil spill and fraudulent financial practices.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11248646.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. The National Plaintiff’s Law Firm of Baron and Budd Handling Granuflo Recall Lawsuits
2. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
3. Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
4. Baron and Budd Has Begun Investigating Claims for Transvaginal Mesh Lawsuits
5. National Law Firm Baron and Budd Helping Women with Alleged Injuries from Lipitor Use Understand the Lipitor Lawsuit
6. Baron and Budd is Encouraged by the First Federal Transvaginal Mesh Lawsuit Verdict
7. Baron and Budd Announces Second Transvaginal Mesh Lawsuit Settlement for Bard
8. GranuFlo Lawsuit Consolidation Supported by Fresenius Medical Care, Bernstein Liebhard LLP Reports
9. GranuFlo Recall Website Launched By Hissey Kientz, LLP Law Firm
10. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
11. GranuFlo Lawsuits Filed in Wake of GranuFlo and NaturaLyte Recall Mount in State and Federal Courts, Bernstein Liebhard LLP Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... LOUIS (PRWEB) , ... April 26, 2017 , ... ... designed specifically to improve the profitability of ready-to-drink, high-protein beverages by helping beverage ... economic alternative to dairy proteins, providing direct cost savings as well as more ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , the ... This new addition to the Mirroring360 product family combines device screen mirroring with ... Pro enables educators, business professionals and individuals to stream or mirror app screens, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... California, committed to raising awareness for Duchenne muscular dystrophy, and funding for ... CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne announced today. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President ... are preparing for how his administration could impact the employee benefits industry. James ... changes are most likely to make it through Congress. His discussion will focus ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  New research provides evidence that an old drug ... a study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... Parkinson,s disease, the oral drug levodopa has long been considered ... as the disease progresses, the effects of the medication can ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology: